Compared to the control group, the percentages of memory T cells in the spleen, including central memory (TCM, CD62L+CD44+) and effector memory T cells (TEM, CD62L-CD44+), increased significantly in the LLC cell rechallenged group (Supplementary Fig. 31, Fig. 8f, g), demonstrating that LRT therapy has effectively established anti-tumor immune memory. The gene discussed is CD44; the disease is neoplasm.